Cite
HARVARD Citation
Rutgeerts, P. et al. (n.d.). OC-005 A Multicenter, Double-Blind, Placebo (PBO)-Controlled Ph3 Study of Ustekinumab (UST), A Human IL-12/23P40 MAB, in Moderate-Severe Crohn's Disease (CD) Refractory to anti-TNFΑ: UNITI-1. Gut. pp. A3-A4. [Online].